DSIP (Delta Sleep-Inducing Peptide)

What is DSIP (Delta Sleep-Inducing Peptide)?

DSIP (Delta Sleep-Inducing Peptide) is a small brain peptide first found in the 1970s, named because it was linked to slow-wave (deep) sleep in animals. It is studied across a range of areas including sleep, the stress response and hormone regulation.

• A nine-amino-acid peptide first isolated from rabbit brain in 1974
• Linked to slow-wave (deep) sleep in animal studies
• Studied in animal research for its effects on the stress response and cortisol
• Also explored in research on hormone regulation and antioxidant activity

For research use only. Not approved for human therapeutic use.

DSIP (CAS 62568-57-4), also known as Delta Sleep-Inducing Peptide and by the INN Emideltide, is a synthetic nonapeptide with the molecular formula C35H48N10O15 and a molecular weight of 848.82 g/mol. Defined by the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, DSIP is classified as an amphiphilic neuropeptide first isolated from rabbit cerebral venous blood in 1977. The N-terminal tryptophan residue provides a characteristic UV absorbance signature used for laboratory identification. Produced via solid-phase peptide synthesis, Delta Sleep-Inducing Peptide is associated with neuroendocrine and circadian signalling pathways.

DSIP has been extensively investigated across a broad range of preclinical neuroendocrine research contexts. The compound has been identified in both free and bound forms within the hypothalamus, limbic system, pituitary, and peripheral tissues, and has been documented as co-localising with multiple peptide and non-peptide mediators including ACTH, melanocyte-stimulating hormone (MSH), and thyroid-stimulating hormone (TSH). Studies examining DSIP immunoreactivity in human pituitary tissue preparations have characterised DSIP’s interaction with neuroendocrine cell populations, documenting its co-localisation with corticotropin-like intermediate lobe peptide (CLIP) in anterior pituitary corticotroph cells and residual intermediate lobe cell populations, establishing a neuroendocrine co-expression pattern within hypophyseal tissue [1]. In vivo rodent studies have examined the relationship between DSIP administration and sleep architecture, with research documenting increases in electroencephalographic slow-wave activity and characterising the interplay between DSIP and endogenous hormonal rhythms, with evidence that endogenous DSIP plays a physiological role in slow-wave sleep and circadian neuroendocrine regulation established through antiserum microinjection studies in rats [2], making DSIP a reference compound in neuropeptide research examining the neuroendocrine and circadian signalling correlates of sleep architecture.

DSIP is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Vallet PG, Charnay Y, Bouras C, Constantinidis J. Distribution and colocalization of delta sleep inducing peptide (DSIP) with corticotropin-like intermediate lobe peptide (CLIP) in the human hypophysis. Neurosci Lett. 1988 Jul 19;90(1–2):78–82. .PubMed PMID: 28427062Iyer KS, Marks GA, Kastin AJ, McCann SM. Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat. Proc Natl Acad Sci U S A. 1988 May;85(10):3653–6. ; PubMed Central PMCID: PMC280272.PubMed PMID: 3368469

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

DSIP (CAS 62568-57-4), also known as Delta Sleep-Inducing Peptide and by the INN Emideltide, is a synthetic nonapeptide with the molecular formula C35H48N10O15 and a molecular weight of 848.82 g/mol. Defined by the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, DSIP is classified as an amphiphilic neuropeptide first isolated from rabbit cerebral venous blood in 1977. The N-terminal tryptophan residue provides a characteristic UV absorbance signature used for laboratory identification. Produced via solid-phase peptide synthesis, Delta Sleep-Inducing Peptide is associated with neuroendocrine and circadian signalling pathways.

DSIP has been extensively investigated across a broad range of preclinical neuroendocrine research contexts. The compound has been identified in both free and bound forms within the hypothalamus, limbic system, pituitary, and peripheral tissues, and has been documented as co-localising with multiple peptide and non-peptide mediators including ACTH, melanocyte-stimulating hormone (MSH), and thyroid-stimulating hormone (TSH). Studies examining DSIP immunoreactivity in human pituitary tissue preparations have characterised DSIP’s interaction with neuroendocrine cell populations, documenting its co-localisation with corticotropin-like intermediate lobe peptide (CLIP) in anterior pituitary corticotroph cells and residual intermediate lobe cell populations, establishing a neuroendocrine co-expression pattern within hypophyseal tissue [1]. In vivo rodent studies have examined the relationship between DSIP administration and sleep architecture, with research documenting increases in electroencephalographic slow-wave activity and characterising the interplay between DSIP and endogenous hormonal rhythms, with evidence that endogenous DSIP plays a physiological role in slow-wave sleep and circadian neuroendocrine regulation established through antiserum microinjection studies in rats [2], making DSIP a reference compound in neuropeptide research examining the neuroendocrine and circadian signalling correlates of sleep architecture.

DSIP is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Vallet PG, Charnay Y, Bouras C, Constantinidis J. Distribution and colocalization of delta sleep inducing peptide (DSIP) with corticotropin-like intermediate lobe peptide (CLIP) in the human hypophysis. Neurosci Lett. 1988 Jul 19;90(1–2):78–82. .PubMed PMID: 28427062Iyer KS, Marks GA, Kastin AJ, McCann SM. Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat. Proc Natl Acad Sci U S A. 1988 May;85(10):3653–6. ; PubMed Central PMCID: PMC280272.PubMed PMID: 3368469

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number62568-57-4Molecular Weight848.81 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUDSIP

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

DSIP (CAS 62568-57-4), also known as Delta Sleep-Inducing Peptide and by the INN Emideltide, is a synthetic nonapeptide with the molecular formula C35H48N10O15 and a molecular weight of 848.82 g/mol. Defined by the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, DSIP is classified as an amphiphilic neuropeptide first isolated from rabbit cerebral venous blood in 1977. The N-terminal tryptophan residue provides a characteristic UV absorbance signature used for laboratory identification. Produced via solid-phase peptide synthesis, Delta Sleep-Inducing Peptide is associated with neuroendocrine and circadian signalling pathways.

DSIP has been extensively investigated across a broad range of preclinical neuroendocrine research contexts. The compound has been identified in both free and bound forms within the hypothalamus, limbic system, pituitary, and peripheral tissues, and has been documented as co-localising with multiple peptide and non-peptide mediators including ACTH, melanocyte-stimulating hormone (MSH), and thyroid-stimulating hormone (TSH). Studies examining DSIP immunoreactivity in human pituitary tissue preparations have characterised DSIP’s interaction with neuroendocrine cell populations, documenting its co-localisation with corticotropin-like intermediate lobe peptide (CLIP) in anterior pituitary corticotroph cells and residual intermediate lobe cell populations, establishing a neuroendocrine co-expression pattern within hypophyseal tissue [1]. In vivo rodent studies have examined the relationship between DSIP administration and sleep architecture, with research documenting increases in electroencephalographic slow-wave activity and characterising the interplay between DSIP and endogenous hormonal rhythms, with evidence that endogenous DSIP plays a physiological role in slow-wave sleep and circadian neuroendocrine regulation established through antiserum microinjection studies in rats [2], making DSIP a reference compound in neuropeptide research examining the neuroendocrine and circadian signalling correlates of sleep architecture.

DSIP is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Vallet PG, Charnay Y, Bouras C, Constantinidis J. Distribution and colocalization of delta sleep inducing peptide (DSIP) with corticotropin-like intermediate lobe peptide (CLIP) in the human hypophysis. Neurosci Lett. 1988 Jul 19;90(1–2):78–82. .PubMed PMID: 28427062Iyer KS, Marks GA, Kastin AJ, McCann SM. Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat. Proc Natl Acad Sci U S A. 1988 May;85(10):3653–6. ; PubMed Central PMCID: PMC280272.PubMed PMID: 3368469

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number62568-57-4Molecular Weight848.81 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUDSIP

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.